Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adaptimmune Therapeutics Plc

ADAP
Current price
0.54 USD +0.0002 USD (+0.04%)
Last closed 0.5 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 123 145 552 USD
Yield for 12 month -72.19 %
Week
Month
Year
ADAP
21.11.2021 - 28.11.2021

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

Analytics

WallStreet Target Price

3.6 USD

P/E ratio

Dividend Yield

Current Year

+27 148 000 USD

Last Year

+6 149 000 USD

Current Quarter

+7 319 000 USD

Last Quarter

+5 130 000 USD

Current Year

+27 148 000 USD

Last Year

+6 149 000 USD

Current Quarter

+7 319 000 USD

Last Quarter

+5 130 000 USD

Key Figures ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -104 721 000 USD
Operating Margin TTM -637.15 %
PE Ratio
Return On Assets TTM -22.49 %
PEG Ratio 0.11
Return On Equity TTM -94.51 %
Wall Street Target Price 3.6 USD
Revenue TTM 71 078 000 USD
Book Value 0.39 USD
Revenue Per Share TTM 0.38 USD
Dividend Share
Quarterly Revenue Growth YOY 4.5 %
Dividend Yield
Gross Profit TTM -100 578 000 USD
Earnings Share -0.54 USD
Diluted Eps TTM -0.54 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -133.94 %

Dividend Analytics ADAP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 30.03.2018

Stock Valuation ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.7835
Price Sales TTM 1.7325
Enterprise Value EBITDA 0.1422
Price Book MRQ 1.3757

Financials ADAP

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ADAP

For 52 weeks

0.42 USD 2.35 USD
50 Day MA 0.6 USD
Shares Short Prior Month 5 846 727
200 Day MA 0.97 USD
Short Ratio 15.48
Shares Short 5 990 432
Short Percent 5.57 %